Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex.
OBJECTIVE
The authors report the first case of Fusarium solani keratitis that progressed to fungal endophthalmitis and was successfully treated with amphotericin B lipid complex (ABLC).


METHODS
The case of a 34-year-old immunocompetent woman who developed a contact lens-related F. solani keratitis requiring emergency penetrating keratoplasty (PKP) was analyzed. The immunocompetent patient developed fungal endophthalmitis (anterior chamber tap positive for F. solani three months after PKP) and was eventually treated with ABLC.


RESULTS
Systemic amphotericin B (total, 0.42 g) and ketoconazole in addition to topical natamycin and amphotericin did not prove to be effective in eradicating the mycosis in the anterior chamber. Under ABLC treatment (total, 8.79 g), the anterior chamber inflammation resolved completely. No recurrence was observed during an 11-month follow-up after treatment was discontinued.


CONCLUSIONS
ABLC proved to be effective in treating F. solani endophthalmitis. It is an important addition to the ophthalmic armamentarium, and appeared to be a better therapeutic agent than standard amphotericin B in this patient.
Goldblum
D
D
Department of Ophthalmology, University of Bern, Switzerland.
Frueh
B E
BE
Zimmerli
S
S
Böhnke
M
M
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000867:Anterior Chamber / Q000382:microbiology / Q000473:pathology; D000935:Antifungal Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005260:Female; D005670:Fusarium / Q000302:isolation & purification*; D006801:Humans; D007634:Keratitis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D009883:Ophthalmic Solutions; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000627:therapeutic use*; D014792:Visual Acuity
D000935:Antifungal Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B